[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-renal-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-renal-failure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,77,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100523473","the-solaris-de-endoprosthesis-for-the-treatment-of-av-access-stenosis-or-occlusion-100523473",false,"NCT06096142","The Solaris DE Endoprosthesis for the Treatment of AV Access Stenosis or Occlusion","Prospective, Randomized, Controlled, Multicenter Study of the Solaris DE Endoprosthesis in the Treatment of Venous Outflow Stenosis or Occlusion in Hemodialysis Patients","DEScover","Inclusion Criteria:\n\n* The participant has a mature AV Fistula (AVF) or Graft (AVG) in the arm created ≥ 30 days before the initial procedure and is in use for dialysis therapy\n* The participant has clinical and\u002For hemodynamic evidence of a venous outflow obstruction or AV fistula or graft dysfunction. The stenotic lesion is ≥ 50%, with a maximum length of 8 cm and a distal reference vessel diameter from 4.0 mm to 9.0 mm\n* The participan provides written informed consent prior to any study-specific procedure\n* The participan is willing to undergo all follow-up evaluations according to the specified schedule over 24 months\n\nAngiographic Inclusion Criteria:\n\n* The target lesion originates ≥ 3 cm from the cannulation segment (needling zone)\n* The target lesion is located:\n\n  1. In one arm (including the cephalic arch) in a participant with AVF, and not in the cannulation segment, OR\n  2. In the anastomosis or juxta-anastomosis in a participant with AVF (a juxta-anastomosis is defined as a location where the stent crosses the venous anastomosis)\n* The target lesion includes a de novo stenotic lesion or restenosis\n* The target lesion is ≥ 5 cm from the arterial anastomosis\n* The target lesion has ≥ 50% stenosis according to the operator's visual judgment\n* The distal reference vessel diameter of the target lesion is between 4.0 mm and 9.0 mm by the operator's visual judgment\n* Single or multiple target lesions measuring ≤ 8 cm in total length by the operator's visual judgment\n* Single or multiple target lesions should be covered by a single stent or multiple overlapping stents, provided they are treated as a single lesion with a maximum length of 8 cm\n* Successful target lesion pre-dilatation is defined as crossover of the guidewir resulting in full expansion of the pre-dilatation balloon\n* The participant has up to 1 (one) non-target lesion in the access circuit requiring intervention in the initial procedure. The non-target lesion must be at least 10 cm away from the target lesion. The non-target lesion can only be treated with standard PTA alone\n* Does not have stent implanted or it has been in the access circuit for ≥ 30 days since placement and patent with ≤ 30% stenosis and located ≥ 5 cm from the target lesion\n* The non-target lesion must be successfully treated at the time of the initial procedure (success measured as ≤30% residual stenosis and no complications).\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding or with intention to become pregnant in the next year\n* The participant has any major endovascular or surgical procedure planned (including in the access circuit) within 30 days of the initial procedure\n* It was not possible to pre-dilate the lesion to be treated with Solaris DE\n* Planned surgical revision of the access site\n* Known or suspected infection of the hemodialysis access site, systemic infection and\u002For sepsis\n* Patients on immunosuppressive therapy\n* Known active coagulopathy or bleeding diathesis\n* Known hypersensitivity to nickel titanium alloy, contrast or sirolimus\n* Contraindication to antiplatelet, anticoagulant or thrombolytic therapies\n* Known allergy to contrast agents or medications administered to perform endovascular intervention that cannot be adequately premedicated\n* Life expectancy of less than 12 months\n* Has a stent or endoprosthesis located anywhere in the AV access circuit that is not patent (\\> 30% stenosis) or implanted \\\u003C 30 days\n* The participant's hemodialysis access is expected to be abandoned within 6 months\n* The participantis is enrolled in another trial involving an investigational product (pharmaceutical, biological or medical device)\n* The patient has a permanent central venous catheter (CVC) for dialysis access, except when its use is temporary, as a bridge to treatment through the access circuit, with a plan for removal after a successful dialysis session after the initial procedure\n\nAngiographic Exclusion Criteria:\n\n* The target lesion is located inside an endoprosthesis\n* Target lesion treatment would involve the cannulation segment (needling zone)\n* The target lesion is \\\u003C 5 cm from the arterial anastomosis\n* There was a dissection or rupture of the treated vessel during the initial treatment that could not be controlled\n* Evidence of an aneurysm, pseudoaneurysm or acute thrombus (i.e. one that has been treated ≤ 15 days) within the target lesion\n* The target lesion is, and\u002For Solaris DE would be placed anywhere:\n\n  1. Through the elbow\n  2. In a region that causes bending of the endoprosthesis or bony protrusion over it\n  3. In the cannulation segment (needling zone)\n  4. Inside any part of a pre-existing stent or endoprosthesis (apart from an access arteriovenous graft)\n  5. Lower extremity\n  6. Non-synthetic graft\n  7. Central thoracic veins located proximal to the cephalic vein arch\n* The target lesion is located in such a way that the insertion of a stent would result in a \"kink\" area that requires a stent bridge between the Solaris DE and an existing stent or stent graft\n* The individual has more than 1 (one) non-target lesion (≥ 50% stenosis) that requires intervention in the initial procedure","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to demonstrate the safety and efficacy of Solaris DE Endoprosthesis in the treatment of stenosis or occlusion within the outflow circuit of the dialysis access including arteriovenous (AV) fistula and synthetic AV graft.\n\nParticipants will be treated with Solaris DE Endoprosthesis. Researchers will compare the treatment with investigational product to Percutaneous Transluminal Angioplasty (PTA) alone within the AV fistula cohort in order to demonstrate superiority of Solaris DE.",[27,28,29],"Venous Stenosis","Venous Occlusion","Chronic Renal Failure","RECRUITING","2026-03-13",{"date":33,"type":34},"2026-03-17","ACTUAL",{"date":36,"type":34},"2024-08-30",{"date":38,"type":21},"2028-02",{"name":40,"class":41},"Scitech Produtos Medicos SA","INDUSTRY",5,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100533565","a-clinical-study-to-map-the-hla-genomic-region-in-the-greek-population-100533565","NCT06227468","A Clinical Study to Map the HLA Genomic Region in the Greek Population","A Clinical Study to Map the HLA GENomic Region and Its potEntial aSsocIation With Selected diSeases in the Greek Population","GENESIS","Inclusion Criteria:\n\nThe study will include adult subjects (age ≥ 18) that:\n\n* possess a Greek social security number and are visiting hospitals\u002Fclinics, and\u002For other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,\n* are willing and able to provide written informed consent to participate in the study according to the study protocol.\n\nExclusion Criteria:\n\n* Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).\n* Subjects who have had an allogeneic (non-self-donor):\n\n  * bone marrow transplant\n  * stem cell transplant\n  * blood transfusion less than two weeks prior to buccal swab sample collection\n  * liver transplant\n* Subjects who participated in an interventional clinical trial in the past that according to the subject's physician opinion might have had an impact on their HLA genome.",true,{"count":53,"type":21},12000,"OBSERVATIONAL","The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.",[57,58,29,59,60,61,62,63,64,65],"Healthy","Respiratory Disease","Cardiovascular Diseases","Metabolic Disease","Psychiatric Disorder","Neurologic Disorder","Gastrointestinal Diseases","Haematologic Disease","Rheumatologic Disease","2024-01-25",{"date":68,"type":34},"2024-01-26",{"date":70,"type":34},"2023-12-12",{"date":72,"type":21},"2026-08-31",{"name":74,"class":75},"Athens LifeTech Park","OTHER",8,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100466454","coronary-rotational-atherectomy-elective-vs-bailout-in-severely-calcified-lesions-and-chronic-renal-failure-100466454","NCT05353946","Coronary Rotational Atherectomy Elective vs. Bailout in Severely Calcified Lesions and Chronic Renal Failure","CRATER Trial: Coronary Rotational Atherectomy Elective vs. Bailout in Patients With Severely Calcified Lesions and Chronic Renal Failure","CRATER","Inclusion Criteria:\n\n* Patients \\>18 years.\n* Glomerular filtration rate (GFR) \\\u003C60 mL\u002Fmin\u002F1.73 m2 for 3 months or more\n* Stenosis ≥70% in a coronary artery with a diameter ≥2,5 mm.\n* Severe angiographic calcification (affecting both sides of the arterial lumen)\n* Any clinical scenario except acute myocardial infarction in the first seven days of evolution.\n* Native coronary vessel or bypass graft.\n\nExclusion Criteria:\n\n* Absence of informed consent.\n* Acute myocardial infarction in the first 7 days of evolution.\n* Lesion in a single patent vessel.\n* Calcified lesions with an angulation \\>60º, dissections, lesions with thrombus, and degenerated saphenous vein grafts.\n* Hemodynamically unstable patients\n* Patients with allergy to iodinated contrast media\n* Patients with significant comorbidity and with a life expectancy of less than one year","100 Years",{"count":87,"type":21},124,[24],"The current role of the rotational atherectomy is for non-dilatable coronary lesions and for severely calcified lesions that may interfere with optimal stent expansion.\n\nSeverely calcified coronary lesions are associated with worse outcomes. In this regard, chronic kidney disease is associated with severely calcified coronary arteries.\n\nSome evidence suggests that elective rotational atherectomy used by experienced operators can be safe and effective, minimizing time and complications for patients with heavily calcified lesions.\n\nHowever, there is no direct randomized comparison between rotational atherectomy and angioplasty alone in the setting of chronic renal failure and with intravascular ultrasound assessment for detecting severely calcified coronary arteries.",[91,29],"Coronary Artery Disease",[93,94,95,96,97],"Severely calcified coronary lesion","Rotational atherectomy","Chronic kidney disease","Intravascular ultrasound","Percutaneous coronary intervention","2022-04-25",{"date":100,"type":34},"2022-04-29",{"date":102,"type":34},"2019-02-02",{"date":104,"type":21},"2023-12-04",{"name":106,"class":75},"Guillermo Galeote; MD, PhD",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":107},"100178992","long-term-safety-and-effectiveness-of-growth-hormone-with-ghd-ts-crf-sga--iss-and-pws-in-children-100178992","NCT01604395","Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children","An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. \u002F Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children","LGS","Inclusion Criteria:\n\n* short stature children aged 2 years or more\n* children with GHD,TS, CRF, SGA or ISS\n* written informed consent from the person, person's parent or legal guardian","2 Years",{"count":118,"type":21},6000,"The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj.\u002FEutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).",[121,122,29,123,124],"Growth Hormone Deficiency","Turner Syndrome","Small for Gestational Age","Idiopathic Short Stature",[126,127,128,129,130,131],"GHD","TS","CRF","SGA","ISS","PWS","2021-02-17",{"date":134,"type":34},"2021-02-21",{"date":136,"type":4},"2012-01",{"date":138,"type":21},"2032-12-31",{"name":140,"class":41},"LG Chem"]